U.S. Small Molecule Innovator API CDMO Market 2030: Continuous Manufacturing
In 2024, the U.S. market for small molecule innovator API CDMOs was valued at USD 8.80 billion, with projections indicating it will expand at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2030. Key drivers fueling this growth include increasing outsourcing by pharmaceutical firms, sustained demand for small-molecule drugs, and the growing number of clinical trials conducted within the U.S. The market is further propelled by rising investments in pharmaceutical R&D, which aim to support the development of innovative small-molecule APIs. Additional contributing factors include heightened demand for new therapies, increasing incidence of cancer, and the growing prevalence of age-related diseases. The expansion of R&D and manufacturing operations within the U.S., coupled with a significant presence of leading pharmaceutical companies, also supports the market's upward trajectory. The emphasis on drug discovery and the increasing number of early-stage R&D init...